



**The beauty of heterogeneity versus  
the need for standardization:  
Enabling trusted data  
consumption in a multi-source,  
multi-ownership data landscape**

**Josef Eiblmaier**

PharmaLex, a Cencora company  
Head of Discovery and Pre-Clinical Research

**cencora**

PharmaLex

The beauty of heterogeneity versus  
the need for standardization:  
Enabling a trusted data consumption in a  
multi-source, multi-ownership data landscape

**Dr. Josef Eiblmaier**

**Chemaxon ChemTalks, Basel, 25.09.2024**

# Agenda

1. PharmaLex and Me at a Glance
2. The Pharmacological Multiverse
3. Case Study: centralized data access platform
4. Conclusion

# PharmaLex and Me at a Glance

# About me

Josef Eiblmaier



- ▶ Chemist by training
- ▶ 22 years in Cheminformatics
- ▶ Management Consultant @ Cencora
- ▶ Experiences in software engineering, data modelling, product and project management & business development





# 40+

## Nationalities

Are on staff, including former us food and drug administration (FDA) and European medicines agency (EMA) **experts**

# 43,000



Projects have been completed successfully



# Lead 40+

Health agency meetings annually, including with EMA / FDA / PMDA / NMPA



# 9/10

of the top pharmaceutical companies are our clients

# 60%

of our client base are small and midsize enterprises



# 50+%

of our projects are global



# 25+

Years of industry experience



# 3,000+

Employees worldwide work with

# 1,600+

 clients

# 200+


Experienced & certified **local representatives** support our global coverage




# 90+%

of our principal consultants hold PHDS

# Global solutions covering the entire product lifecycle



**We offer the whole spectrum — *from* higher-value, project-based consulting work to longer, larger and holistic outsourcing solutions — globally.**



# The Pharmacological Multiverse






# Data Scientists and AI Specialists Pain Points



## Consequence:

# What data scientists spend the most time doing?



## Why?

Data are fragmented over systems and locations and are mismatching.

Need to be transformed into actionable information to create analytics, insights and visualisations.

Manual processing is time-consuming and costly.

## In short: the data is not ...



Findable




Accessible



Interoperable



Reusable



Source: Calvin and Hobbes

# Case Study: centralized Data Access Platform

# Initial Situation and Vision



7 sites




Decentralised  
data landscape



Multiple  
access systems



No common  
vocabularies



## One Data Access Vision

Design and implement ONE centralized architecture and ONE solution for global scientific data access across Evotec, to allow better data integration and support current/future needs for data access and consumption.



Global scientific  
data access



Data  
awareness  
improvement



Predictive  
Modelling

# The Data Virtualization/Data Warehouse Hybrid approach



## One central access platform allowing

- Access control, logging and monitoring
- Easy connection and aggregation of data sources (REST, SOAP, ODBC/JDBC)
- Data in real time, on the fly aggregation



**Data Virtualization**

.....

## Data storage platform allowing

- Complex & multi-step data transformations, data harmonization and enrichment
- Performant access quicker than access to the source system
- Unified corporate wide data model including Reference, Master and Transactional Data




**Data  
Replication**

**One Data Acces**

# The solution



Data consumers in multiple sites



ODA On-Prem Data Center Fra.

Data sources from multiple sites





# One Data Access Key Benefits




## Data Access

Company wide, unified, smooth, and access controlled access to research data



## Integrated Data Model

Inter connecting all major business entities in one data model including harmonization



## Data Awareness

Data catalog allows search & browsing in data and meta data



## Data Centricity

The connecting bridge enabling multi purpose use of data assets in different use cases



# Conclusion

# Conclusion

- **There are various ways to build bridges between discrete data universes such as data replication, data virtualization, and data harmonization, ...**
- **By combining data replication and data virtualisation, we create a future-proof, high-performance, and scalable data access platform for heterogeneous and distributed R&D data.**
- **Questions? Happy to discuss!**





@ [contact@pharmalex.com](mailto:contact@pharmalex.com)

🌐 [pharmalex.com](https://pharmalex.com)

in [pharmalexglobal](https://pharmalexglobal)

# Thank you

© 2024 PharmaLex GmbH. All Rights Reserved.



Cencora PharmaLex is supporting [Treedom](#), a platform that allows us to plant trees and follow them online – not only does it benefit the environment, but it also delivers on our social mission.

**CONFIDENTIALITY:** This document and any accompanying information are provided in strict confidence, for the sole and exclusive use of the receiving party and may not be disclosed to any third party or used in whole or in part for any other purpose without the written permission of Cencora PharmaLex or any of its affiliates.

# Copyright & Disclaimers

*The information provided in this presentation does not constitute legal advice. PharmaLex GmbH, and its parent Cencora, Inc., strongly encourage the audience to review available information related to the topics discussed during the presentation and to rely on their own experience and expertise in making decisions related thereto.*



**The beauty of heterogeneity versus  
the need for standardization:  
Enabling trusted data  
consumption in a multi-source,  
multi-ownership data landscape**

**Josef Eiblmaier**

PharmaLex, a Cencora company  
Head of Discovery and Pre-Clinical Research